Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V010
- Development stage
- Preclinical
- Lead developer
- Changzhou Siyao Pharmaceuticals
- Modality
- Cell Therapies, Gene Therapies
01
Overview
V010 is a proprietary research project and therapeutic platform under development by Changzhou Siyao Pharmaceuticals in collaboration with the Changzhou Siyao Israel Biological Research Institute (常州四药中以生物研究院). Described as an industry-first platform, V010 integrates cell therapy and gene therapy technologies to facilitate the development of novel biological macromolecule drugs. While specific molecular targets and clinical phases have not been publicly disclosed, the project is part of the company's strategic focus on high-end biological innovation in therapeutic areas such as cardiovascular diseases, gynecology, and neurodegenerative disorders.
Beyond the preview
Go deeper on V010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V010.